Amerikanische Gesellschaft für Hirudotherapie

Ravimiamet — State Agency of Medicines of Estonia

Ravimiamet · Estonia · europe

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Estonia's State Agency of Medicines — leeches fall under EU medical-device frameworks (MDR 2017/745) as implemented through Estonian national law; leech-specific national authorisation has not been independently verified by ASH.

Regulatory Profile

Agency type
national regulator
Region
europe
Country
Estonia
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • Estonian Medicinal Products Act
  • EU Medical Device Regulation (MDR) 2017/745 — as transposed into Estonian law
  • Estonian Health Services Organisation Act

Prescriber Requirements

  • Estonian Health Board–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

Ravimiamet registration as applicable; Estonian-language labelling required per Language Act. Standard cold-chain conditions; EU intra-community movement under MDR applies.

Import/Export Rules

Free movement within the EU single market under MDR; veterinary services clearance for live invertebrates from non-EU origin; CITES Appendix II paperwork for Hirudo medicinalis / verbana on extra-EU import.

Reimbursement Context

Estonian Health Insurance Fund (Eesti Haigekassa) coverage depends on inpatient bundling; outpatient hirudotherapy is generally not separately reimbursed.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general EU MDR framework as transposed into Estonian law. Baltic states often harmonise on EU medicines and device interpretation; whether leech-specific guidance exists has not been independently mapped by ASH.

Related Jurisdictions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.